Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Orange Book Blog: At the Intersection of Patent Law and FDA Law

Intellectual Property Law

: Orange Book Blog: At the Intersection of Patent Law and FDA Law

Pharma News Briefs

By Aaron Barkoff

• Eisai announced yesterday that the district court in New Jersey recently dismissed its lawsuit against Mutual Pharma concerning Aricept ODT.  The case was dismissed on jurisdictional grounds because Mutual has not challenged Eisai's patent.
• The Wall St. Journal had an interesting article Wednesday about Sun Pharma's generic version of Wyeth's blockbuster antidepressant Effexor XR.  AP published this related story last week.
• On Monday, Teva announced that it launched generic Protonix (pantoprazole).  In response, Wyeth announced that it will pursue monetary damages from Teva.  For more, see Pharmalot and the WSJ Health Blog.  As we previously reported, in September a district court denied Wyeth's motion for a preliminary injunction against Teva.
• FDA Law Blog reported last week that the district court in Washington, D.C. enjoined the federal government's Average Manufacturer Price (AMP) rule for pharmaceutical reimbursement.
• Pharmalot had an interesting post last week about a recent report on the various types of pharmaceuticals in Phase I studies.
• Depomed announced on December 13 that a district court in California granted summary judgment of infringement in its patent case against IVAX concerning generic Glumetza.
• AstraZeneca announced on December 12 that it filed patent infringement suits against seven generic drug makers who filed ANDAs for generic versions of Crestor (rasuvastatin calcium).  See also this Reuters article.

Full post as published by Orange Book Blog: At the Intersection of Patent Law and FDA Law on December 28, 2007 (boomark / email).